CUVL
Clinuvel Pharmaceuticals Limited
Price Chart
Latest Quote
$5.02
+0.06 (+1.21%)
Current Price
| Previous Close | $4.96 |
| Open | $4.98 |
| Day High | $5.04 |
| Day Low | $4.98 |
| Volume | 3,225 |
Stock Information
Note: Financial values converted from AUD to USD
| Quarterly Dividend / Yield | $0.04 / 0.73% |
| Shares Outstanding | 50.49M |
| Quarterly Dividend Yield | 0.73% |
| Quarterly Dividend | $0.04 |
| Total Debt | $1.36M |
| Cash Equivalents | $177.15M |
| Revenue | $66.08M |
| Net Income | $23.84M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $253.45M |
| P/E Ratio | 11.16 |
| EPS (TTM) | $0.45 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5K |
| Sales | $66.08M |
| Income | $23.84M |
| Book/sh | $3.80 |
| Cash/sh | $4.99 |
Financial Ratios
| Quick Ratio | 14.34 |
| Current Ratio | 14.81 |
| Debt/Eq | 0.71 |
| EPS Growth TTM | 6.20% |
Returns & Margins
| ROA | 8.94% |
| ROE | 13.21% |
| Gross Margin | 83.18% |
| Operating Margin | 47.32% |
| Profit Margin | 36.07% |
Ownership
| Institutional Ownership | 0.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 2.70 |
| P/B | 1.32 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $5.41 |
| SMA50 | $5.95 |
| SMA200 | $6.81 |
| RSI | 20.00 |
| ATR | 0.1964 |
| Shares Float | 42.06M |
| Short Ratio | 0.54 |
| Volatility | 0.58 |
| Rel Volume | 0.51 |
Performance History
| Week | -3.28% |
| Month | -12.70% |
| Quarter | -26.09% |
| 6 Months | -23.86% |
| YTD | -37.83% |
| Year | -33.23% |
| 3 Years | -49.39% |
| 5 Years | -83.25% |
| 10 Years | -23.73% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $5.02 | 3,225 |
| 2026-10-26 | $4.96 | 5,300 |
| 2026-10-23 | $4.94 | 4,700 |
| 2026-10-22 | $5.03 | 23,800 |
| 2026-10-21 | $5.12 | 700 |
| 2026-10-20 | $5.19 | 3,100 |
| 2026-10-19 | $5.24 | 5,400 |
| 2026-10-16 | $5.24 | 3,200 |
| 2026-10-15 | $5.06 | 3,400 |
| 2026-10-14 | $5.30 | 3,600 |
| 2026-10-13 | $5.44 | 5,000 |
| 2026-10-12 | $5.58 | 10,500 |
| 2026-10-09 | $5.59 | 1,600 |
| 2026-10-08 | $5.60 | 13,800 |
| 2026-10-07 | $5.80 | 2,200 |
| 2026-10-06 | $5.67 | 3,500 |
| 2026-10-05 | $5.74 | 9,600 |
| 2026-10-02 | $6.03 | 1,000 |
| 2026-10-01 | $5.66 | 10,400 |
| 2026-09-30 | $5.96 | 13,100 |
| 2026-09-29 | $5.87 | 2,200 |
| 2026-09-28 | $5.75 | 8,700 |
About Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÃNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
đ° Latest News
No news articles available at the moment. Check back later for updates on CUVL.
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $11,129,370 | $11,176,190 | $7,095,085 | $6,185,883 |
| Cost Of Revenue | $11,129,370 | $11,176,190 | $7,095,085 | $6,185,883 |
| Total Revenue | $66,172,425 | $66,871,399 | $62,058,068 | $55,120,922 |
| Operating Revenue | $66,172,425 | $66,871,399 | $62,058,068 | $55,120,922 |
| Expenses | ||||
| Other Income Expense | $-2,334,311 | $599,555 | $-138,956 | $537,041 |
| Other Non Operating Income Expenses | $-2,334,311 | $599,555 | $-138,956 | $537,041 |
| Net Non Operating Interest Income Expense | $7,350,992 | $3,496,152 | $2,020,254 | $501,895 |
| Operating Expense | $27,211,332 | $23,509,123 | $21,177,466 | $17,896,614 |
| Selling And Marketing Expense | $5,922,738 | - | - | - |
| General And Administrative Expense | $7,862,897 | $18,899,355 | $17,612,215 | $15,882,004 |
| Interest Expense | - | $3,140,853 | $3,134,839 | $2,246,965 |
| Interest Expense Non Operating | - | $3,140,853 | $3,134,839 | $2,246,965 |
| Other Operating Expenses | - | $3,778,328 | $2,761,306 | $1,459,041 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $23,869,955 | $25,457,469 | $25,080,132 | $21,538,860 |
| Net Interest Income | $7,350,992 | $3,496,152 | $2,020,254 | $501,895 |
| Interest Income | $7,350,992 | $6,637,005 | $5,155,093 | $2,748,861 |
| Normalized Income | $23,869,955 | $25,457,469 | $25,080,132 | $21,538,860 |
| Net Income From Continuing And Discontinued Operation | $23,869,955 | $25,457,469 | $25,080,132 | $21,538,860 |
| Net Income Common Stockholders | $23,869,955 | $25,457,469 | $25,080,132 | $21,538,860 |
| Net Income | $23,869,955 | $25,457,469 | $25,080,132 | $21,538,860 |
| Net Income Including Noncontrolling Interests | $23,869,955 | $25,457,469 | $25,080,132 | $21,538,860 |
| Net Income Continuous Operations | $23,869,955 | $25,457,469 | $25,080,132 | $21,538,860 |
| Pretax Income | $33,541,956 | $36,281,793 | $35,666,816 | $32,077,362 |
| Interest Income Non Operating | $7,350,992 | $6,637,005 | $5,155,093 | $2,748,861 |
| Operating Income | $27,831,723 | $32,186,086 | $33,785,517 | $31,038,425 |
| Depreciation Amortization Depletion Income Statement | $693,552 | $831,441 | $803,945 | $555,569 |
| Depreciation And Amortization In Income Statement | $693,552 | $831,441 | $803,945 | $555,569 |
| Depreciation Income Statement | $693,552 | $831,441 | $803,945 | $555,569 |
| Gross Profit | $55,043,055 | $55,695,209 | $54,962,983 | $48,935,039 |
| Per Share | ||||
| Diluted EPS | $0.47 | $0.51 | $0.49 | $0.42 |
| Basic EPS | $0.48 | $0.51 | $0.50 | $0.44 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $28,525,275 | $40,254,087 | $39,605,600 | $34,879,896 |
| Reconciled Depreciation | $693,552 | $831,441 | $803,945 | $555,569 |
| EBITDA (Bullshit earnings) | $28,525,275 | $40,254,087 | $39,605,600 | $34,879,896 |
| EBIT | $27,831,723 | $39,422,647 | $38,801,654 | $34,324,327 |
| Diluted Average Shares | $35,733,466 | $35,456,086 | $35,931,421 | $36,444,772 |
| Basic Average Shares | $35,195,963 | $35,242,484 | $35,072,162 | $34,773,973 |
| Tax Provision | $9,672,001 | $10,824,324 | $10,586,684 | $10,538,502 |
| Research And Development | $12,732,145 | - | - | - |
| Selling General And Administration | $13,785,635 | $18,899,355 | $17,612,215 | $15,882,004 |
| Other Gand A | $7,862,897 | - | - | - |
| Salaries And Wages | - | $18,899,355 | $17,612,215 | $15,882,004 |
Fetched: 2026-10-25
Balance Sheet (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $191,917,986 | $169,345,906 | $142,744,977 | $115,733,770 |
| Total Assets | $207,679,098 | $191,252,033 | $162,659,970 | $136,331,591 |
| Total Non Current Assets | $7,361,925 | $6,179,727 | $6,376,034 | $2,882,510 |
| Non Current Deferred Assets | $571,650 | $883,558 | $718,097 | $745,683 |
| Non Current Deferred Taxes Assets | $571,650 | $883,558 | $718,097 | $745,683 |
| Goodwill And Other Intangible Assets | $130,220 | $130,220 | $130,220 | $130,220 |
| Other Intangible Assets | $130,220 | $130,220 | $130,220 | - |
| Current Assets | $200,317,173 | $185,072,306 | $156,283,935 | $133,449,081 |
| Other Current Assets | $1,576,753 | $1,816,175 | $936,351 | - |
| Inventory | $4,842,963 | $6,208,270 | $7,478,790 | $6,699,600 |
| Receivables | $16,506,091 | $19,326,738 | $18,465,970 | $15,634,208 |
| Other Receivables | $3,334,611 | $2,319,302 | $862,303 | $1,106,971 |
| Accounts Receivable | $13,171,480 | $17,115,085 | $17,708,886 | $14,644,176 |
| Cash Cash Equivalents And Short Term Investments | $177,391,366 | $157,721,123 | $129,402,824 | $110,362,121 |
| Cash And Cash Equivalents | $177,391,366 | $157,721,123 | $129,402,824 | $110,362,121 |
| Cash Equivalents | $163,812,464 | $139,353,630 | $116,661,226 | $94,256,851 |
| Cash Financial | $13,578,902 | $18,367,493 | $12,741,598 | $16,105,271 |
| Receivables Adjustments Allowances | - | $-107,649 | $-105,219 | $-116,939 |
| Prepaid Assets | - | - | - | $753,152 |
| Debt | ||||
| Total Debt | $1,364,266 | $371,967 | $619,174 | $703,684 |
| Long Term Debt And Capital Lease Obligation | $1,090,767 | $68,509 | $358,873 | $491,957 |
| Current Debt And Capital Lease Obligation | $273,499 | $303,458 | $260,301 | $211,727 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,630,891 | $21,775,907 | $19,784,772 | $20,467,600 |
| Total Non Current Liabilities Net Minority Interest | $2,107,133 | $2,625,550 | $2,040,950 | $2,524,949 |
| Non Current Deferred Liabilities | $835,946 | $2,406,955 | $1,566,686 | $1,940,683 |
| Non Current Deferred Taxes Liabilities | $835,946 | $2,406,955 | $1,566,686 | $1,940,683 |
| Current Liabilities | $13,523,758 | $19,150,357 | $17,743,822 | $17,942,651 |
| Current Deferred Liabilities | $4,725,399 | $10,237,902 | $11,155,877 | $11,326,749 |
| Current Deferred Taxes Liabilities | $4,725,399 | $10,237,902 | $11,155,877 | $11,326,749 |
| Payables And Accrued Expenses | $6,507,041 | $6,998,785 | $5,003,204 | $5,383,610 |
| Payables | $6,507,041 | $6,998,785 | $5,003,204 | $5,383,610 |
| Other Payable | $5,606,733 | $5,203,728 | $3,352,535 | $3,418,889 |
| Accounts Payable | $900,308 | $1,795,057 | $1,650,669 | $1,964,721 |
| Equity | ||||
| Common Stock Equity | $192,048,207 | $169,476,126 | $142,875,197 | $115,863,991 |
| Total Equity Gross Minority Interest | $192,048,207 | $169,476,126 | $142,875,197 | $115,863,991 |
| Stockholders Equity | $192,048,207 | $169,476,126 | $142,875,197 | $115,863,991 |
| Gains Losses Not Affecting Retained Earnings | $3,892,161 | $5,556,923 | $2,987,804 | $15,874,477 |
| Other Equity Adjustments | $1,245,842 | $1,738,039 | - | $13,632,237 |
| Retained Earnings | $66,889,333 | $44,782,973 | $21,087,780 | $-6,878,933 |
| Other | ||||
| Ordinary Shares Number | $35,490,111 | $35,275,973 | $35,243,705 | $34,773,973 |
| Share Issued | $35,490,111 | $35,275,973 | $35,243,705 | $34,773,973 |
| Tangible Book Value | $191,917,986 | $169,345,906 | $142,744,977 | $115,733,770 |
| Invested Capital | $192,048,207 | $169,476,126 | $142,875,197 | $115,863,991 |
| Working Capital | $186,793,415 | $165,921,949 | $138,540,113 | $115,506,430 |
| Capital Lease Obligations | $1,364,266 | $371,967 | $619,174 | $703,684 |
| Total Capitalization | $192,048,207 | $169,476,126 | $142,875,197 | $115,863,991 |
| Foreign Currency Translation Adjustments | $2,646,319 | $3,818,885 | $2,987,804 | $2,242,239 |
| Capital Stock | $121,266,712 | $119,136,230 | $118,799,612 | $106,868,447 |
| Common Stock | $121,266,712 | $119,136,230 | $118,799,612 | $106,868,447 |
| Employee Benefits | $84,846 | $89,934 | $59,625 | $39,815 |
| Non Current Pension And Other Postretirement Benefit Plans | $84,846 | $89,934 | $59,625 | $39,815 |
| Long Term Capital Lease Obligation | $1,090,767 | $68,509 | $358,873 | $491,957 |
| Long Term Provisions | $95,574 | $60,153 | $55,766 | $52,494 |
| Current Capital Lease Obligation | $273,499 | $303,458 | $260,301 | $211,727 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,017,820 | $1,610,211 | $1,324,441 | $1,020,564 |
| Investments And Advances | $153,149 | $150,144 | $94,453 | - |
| Other Investments | $153,149 | $150,144 | $94,453 | - |
| Net PPE | $6,506,906 | $5,015,804 | $5,433,264 | $2,006,606 |
| Accumulated Depreciation | $-2,429,668 | $-2,692,308 | $-2,068,703 | $-1,655,851 |
| Gross PPE | $8,936,574 | $7,708,112 | $7,501,967 | $3,662,457 |
| Leases | $1,398,409 | $1,398,409 | $1,398,409 | $1,328,769 |
| Construction In Progress | $870,476 | - | - | - |
| Other Properties | $1,769,498 | $1,307,407 | $1,305,478 | $1,286,895 |
| Machinery Furniture Equipment | $1,368,197 | $1,472,303 | $1,301,867 | $1,046,793 |
| Land And Improvements | $3,529,993 | $3,529,993 | $3,496,213 | - |
| Finished Goods | $2,480,088 | $2,086,604 | $2,131,472 | $1,118,945 |
| Work In Process | $1,810,510 | $3,640,396 | $4,945,341 | $5,254,695 |
| Raw Materials | $552,365 | $481,270 | $401,977 | $362,314 |
| Goodwill | - | - | - | $130,220 |
| Inventories Adjustments Allowances | - | - | - | $-36,354 |
Fetched: 2026-10-25
Cash Flow Statement (Annual)
| Metric | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $24,848,919 | $28,712,012 | $22,153,330 | $25,254,790 |
| Operating Activities | ||||
| Cash Flowsfromusedin Operating Activities Direct | $25,976,331 | $28,922,137 | $26,077,755 | $25,977,946 |
| Classesof Cash Receiptsfrom Operating Activities | $70,094,244 | $66,027,652 | $59,521,378 | $52,712,879 |
| Other Cash Receiptsfrom Operating Activities | - | $1 | $146,804 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,127,412 | $-210,125 | $-3,924,425 | $-723,156 |
| Investing Cash Flow | $-27,530,308 | $-33,581,627 | $-20,433,476 | $-723,156 |
| Cash Flow From Continuing Investing Activities | $-27,530,308 | $-33,581,627 | $-20,433,476 | $-723,156 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-396,908 | $-310,301 | $-3,455,026 | - |
| Issuance Of Capital Stock | $396,908 | $133,014 | $2,924,210 | - |
| Financing Cash Flow | $-1,938,842 | $-2,068,144 | $-2,513,764 | $-1,576,559 |
| Cash Flow From Continuing Financing Activities | $-1,938,842 | $-2,068,144 | $-2,513,764 | $-1,576,559 |
| Net Other Financing Charges | $-175,247 | $-128,581 | $-488,907 | $-371,199 |
| Cash Dividends Paid | $-1,763,595 | $-1,762,277 | $-1,738,495 | $-1,390,959 |
| Common Stock Dividend Paid | $-1,763,595 | $-1,762,277 | $-1,738,495 | $-1,390,959 |
| Net Common Stock Issuance | $0 | $-177,286 | $-530,816 | - |
| Common Stock Issuance | $396,908 | $133,014 | $2,924,210 | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $16,443,605 | $11,067,492 | $11,012,817 | $5,450,716 |
| End Cash Position | $15,054,972 | $19,720,357 | $24,773,560 | $110,362,121 |
| Beginning Cash Position | $19,720,357 | $24,773,560 | $22,445,648 | $85,515,717 |
| Effect Of Exchange Rate Changes | $-1,172,565 | $1,674,432 | $-802,603 | $1,168,172 |
| Changes In Cash | $-3,492,820 | $-6,727,635 | $3,130,515 | $23,678,232 |
| Common Stock Payments | $-396,908 | $-310,301 | $-3,455,026 | - |
| Net Investment Purchase And Sale | $-26,402,897 | $-33,371,502 | $-16,509,051 | - |
| Purchase Of Investment | $-26,402,897 | $-33,371,502 | $-16,509,051 | - |
| Net PPE Purchase And Sale | $-1,127,412 | $-210,125 | $-3,924,425 | $-723,156 |
| Purchase Of PPE | $-1,127,412 | $-210,125 | $-3,924,425 | $-723,156 |
| Taxes Refund Paid Direct | $-16,443,605 | $-11,067,492 | $-10,840,991 | $-5,267,084 |
| Interest Received Direct | $6,703,682 | $5,243,376 | $5,371,980 | $1,919,295 |
| Classesof Cash Payments | $-34,377,991 | $-31,281,399 | $-27,974,611 | $-23,387,144 |
| Paymentsto Suppliersfor Goodsand Services | $-34,377,991 | $-31,281,399 | $-27,974,611 | $-23,387,144 |
| Receiptsfrom Government Grants | $453,863 | $17,019 | $242,377 | $15,489 |
| Receiptsfrom Customers | $69,640,381 | $66,010,631 | $59,132,196 | $52,697,389 |
Fetched: 2026-10-25